Biotechnology

Optimizing human performance & longevity through peptide science. ⚡️ Exploring BPC-157, NAD+, Epitalon, and the future of anti-aging. 🧪 Science-backed insights

[Biotechnology @zeelee01]

Eli Lilly's GLP-1R/GIPR/GCGR triple-agonist Retatrutide is in Phase III clinical trials, while multiple domestic long-acting single/dual-target peptides (such as Signality Pharmaceuticals' Ecnoglutide) have also fully entered the Phase III registration clinical race.#peptides

[Biotechnology @zeelee01]

FibroBiologics filed a U.S. patent for engineered cells designed to continuously produce GLP-1, GIP and GLP-2 peptides inside the body.
Key question: Can continuous peptide delivery improve convenience without compromising safety?#Retatrutide #Peptides #PeptideScience

[Biotechnology @zeelee01]

Late-stage survodutide trials face attention after nearly 20% of participants discontinued treatment, mainly due to gastrointestinal side effects.#Retatrutide #Peptides #PeptideScience

[Biotechnology @zeelee01]

Medisca launched a global peptide division focused on API-grade peptides, manufacturing partnerships and pharma infrastructure as the peptide market expands.#Retatrutide #Peptides #PeptideScience

[Biotechnology @zeelee01]

CUHK’s novel peptide candidate for Huntington’s disease received FDA Orphan Drug Designation, highlighting growing interest in peptide therapeutics.#Retatrutide #Peptides #PeptideScience

[Biotechnology @zeelee01]

Clear picture, thank you. We source from established Asian API capacity but only sell with batch docs, not as research-only kits. Happy to quote specific SKUs if you want to compare.

[Biotechnology @zeelee01]

Asia now holds ~45–50% of peptide API volume; China is about a third. The U.S. is splitting licensed compounding from online “research” kits (warning letters still going out). Samsung’s PolyPeptide deal shows big-pharma manufacturing is consolidating.

[Biotechnology @zeelee01]

CUHK’s 21-amino-acid peptide for Huntington’s disease won FDA Orphan Drug Designation. The candidate targets expanded CAG-repeat RNA and remains preclinical.
#Retatrutide #Peptides #PeptideScience

[Biotechnology @zeelee01]

2025–26: research-peptide shops shut, CBP flagged ~5,000 mislabeled China vials, Lilly sued unapproved retatrutide sellers. “Research only” labels are under fire. (154)#Retatrutide #Peptides #PeptideScience

[Biotechnology @zeelee01]

Ascletis has started a U.S. Phase I trial of ASC36, an oral amylin receptor peptide agonist being developed for obesity.#Retatrutide #Peptides #PeptideScience

[Biotechnology @zeelee01]

5th Circuit upheld FDA: semaglutide and tirzepatide shortages are over. Mass compounding of GLP-1 copies loses that legal hook.#Retatrutide #Peptides #PeptideScience

[Biotechnology @zeelee01]

@peptideindexhq Exactly. Regulatory access may change, but quality verification doesn’t. Lot-specific COAs, identity testing, purity data, and clear labeling remain essential for evaluating what’s actually in the vial.

[Biotechnology @zeelee01]

FDA is tightening compounded GLP-1s, moving to keep semaglutide, tirzepatide and liraglutide off the 503B bulk list.#Retatrutide #Peptides #PeptideScience

[Biotechnology @zeelee01]

Oral GLP-1 race: Wegovy pill ~183k weekly Rx vs Lilly’s Foundayo 47.5k. Total GLP-1 scripts +5.4% in 4 weeks (IQVIA/Citi).#Retatrutide #Peptides #PeptideScience

[Biotechnology @zeelee01]

FDA panel narrowly backed compounding review for BPC-157, KPV, TB-500 and MOTS-c. Not an approval—rulemaking still ahead. Peptide policy is moving fast.#Retatrutide #Peptides #PeptideScience

[Biotechnology @zeelee01]

GLP-1 is not a trend. It’s a rewrite of hunger. Semaglutide and tirzepatide didn’t just cut weight ,They changed what people expect from medicine.
#Retatrutide #Peptides #PeptideScience

[Biotechnology @zeelee01]

@peptidemom Absolutely agree. We believe transparency starts with batch-level documentation. COA, HPLC purity data, and testing details should be available for verification. In peptide sourcing, reliable data matters more than marketing claims.

[Biotechnology @zeelee01]

Peptides are trending. Misinformation is too
As peptide therapy gains attention, it’s becoming harder to separate science from hype.
1️⃣ Who should guide peptide use
2️⃣ Where should peptides come from
3️⃣ Natural vs. synthetic peptides
4️⃣ Why popularity doesn’t equal suitability

[Biotechnology @zeelee01]

Peptide regulation is changing.
FDA scrutiny is rising around unapproved peptides.
Solution: Verify identity, purity, batch data, testing and regulatory status.
Science > hype.
#Peptides #Biotech

[Biotechnology @zeelee01]

Peptide Regulation Is Tightening
The peptide market is expanding, but regulators are paying closer attention to unapproved GLP-1 and other peptide products especially those labeled “research use” while implying human use.
Check: Identity Purity Batch HPLC/MS Regulatory status

[Biotechnology @zeelee01]

🧬 Peptide therapy is entering a new regulatory era.

FDA has proposed removing semaglutide, tirzepatide & liraglutide from the 503B bulk list
For peptide users, source, regulation and quality matter more than ever.
Science first. Hype second.
#Peptides #GLP1 #PeptideScience #FDA